Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

被引：0
作者：
Tetsu Hayashida
Hiromitsu Jinno
Katsuaki Mori
Hiroki Sato
Akira Matsui
Takashi Sakurai
Hiroaki Hattori
Shin Takayama
Masahiro Wada
Maiko Takahashi
Hirohito Seki
Tomoko Seki
Aiko Nagayama
Akiko Matsumoto
Yuko Kitagawa
机构：
[1] Keio University School of Medicine,Department of Surgery
[2] Teikyo University School of Medicine,Department of Surgery
[3] Hino Municipal Hospital,Department of Surgery
[4] Mito Red Cross Hospital,Department of Surgery
[5] National Hospital Organization Tokyo Medical Center,Department of Surgery
[6] JCHO Saitama Medical Center,Division of Surgery
[7] Federation of National Public Service Personnel Mutual Aid Associations,Department of Surgery
[8] Tachikawa Hospital,Department of surgery
[9] Tokyo Dental College Ichikawa General Hospital,Department of Surgery
[10] Sanokousei general hospital,undefined
来源：
BMC Cancer | / 18卷
关键词：
Breast cancer; Eribulin; Phase II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Digital phenotyping in young breast cancer patients treated with neoadjuvant chemotherapy (the NeoFit Trial): protocol for a national, multicenter single-arm trial
    Delrieu, Lidia
    Hamy, Anne-Sophie
    Coussy, Florence
    Kassara, Amyn
    Asselain, Bernard
    Antero, Juliana
    De Villele, Paul
    Dumas, Elise
    Forstmann, Nicolas
    Guerin, Julien
    Hotton, Judicael
    Jouannaud, Christelle
    Milder, Maud
    Leopold, Armand
    Sedeaud, Adrien
    Soibinet, Pauline
    Toussaint, Jean-Francois
    Vercamer, Vincent
    Laas, Enora
    Reyal, Fabien
    BMC CANCER, 2022, 22 (01)
  • [42] Capecitabine and vinorelbine as first-line treatment in elderly patients (≥65 years) with metastatic breast cancer -: A phase II trial (SAKK 25/99)
    Hess, D.
    Koeberle, D.
    Thuerlimann, B.
    Pagani, O.
    Schoenenberger, A.
    Mattmann, S.
    Rochlitz, C.
    Rauch, D.
    Schuller, J. C.
    Ballabeni, P.
    Ribi, K.
    ONCOLOGY, 2007, 73 (3-4) : 228 - 237
  • [43] A Phase II Trial of Second-Line Axitinib Following Prior Antiangiogenic Therapy in Advanced Hepatocellular Carcinoma
    McNamara, Mairead G.
    Le, Lisa W.
    Horgan, Anne M.
    Aspinall, Alex
    Burak, Kelly W.
    Dhani, Neesha
    Chen, Eric
    Sinaei, Mehrdad
    Lo, Glen
    Kim, Tae Kyoung
    Rogalla, Patrik
    Bathe, Oliver F.
    Knox, Jennifer J.
    CANCER, 2015, 121 (10) : 1620 - 1627
  • [44] Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
    Pellegrino, B.
    Cavanna, L.
    Boggiani, D.
    Zamagni, C.
    Frassoldati, A.
    Schirone, A.
    Caldara, A.
    Rocca, A.
    Gori, S.
    Piacentini, F.
    Berardi, R.
    Brandes, A. A.
    Foglietta, J.
    Villa, F.
    Todeschini, R.
    Tognetto, M.
    Naldi, N.
    Bortesi, B.
    Montemurro, F.
    Ardizzoni, A.
    Boni, L.
    Musolino, A.
    ESMO OPEN, 2021, 6 (01)
  • [45] Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
    Schwartzberg, Lee
    McIntyre, Kristi
    Wilks, Sharon
    Puhalla, Shannon
    O'Shaughnessy, Joyce
    Berrak, Erhan
    He, Yaohua
    Vahdat, Linda
    BMC CANCER, 2019, 19 (1)
  • [46] Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer
    Kristi McIntyre
    Joyce O’Shaughnessy
    Lee Schwartzberg
    Stefan Glück
    Erhan Berrak
    James X. Song
    David Cox
    Linda T. Vahdat
    Breast Cancer Research and Treatment, 2014, 146 : 321 - 328
  • [47] Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
    Lee Schwartzberg
    Kristi McIntyre
    Sharon Wilks
    Shannon Puhalla
    Joyce O’Shaughnessy
    Erhan Berrak
    Yaohua He
    Linda Vahdat
    BMC Cancer, 19
  • [48] Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer
    Zhao, Qi
    Hughes, Rachel
    Neupane, Binod
    Mickle, Kristin
    Su, Yun
    Chabot, Isabelle
    Betts, Marissa
    Kadambi, Ananth
    BMC CANCER, 2021, 21 (01)
  • [49] Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer
    Qi Zhao
    Rachel Hughes
    Binod Neupane
    Kristin Mickle
    Yun Su
    Isabelle Chabot
    Marissa Betts
    Ananth Kadambi
    BMC Cancer, 21
  • [50] RADIOSENSITIZATION OF CHEMOTHERAPY-REFRACTORY, LOCALLY ADVANCED OR LOCALLY RECURRENT BREAST CANCER WITH TRASTUZUMAB: A PHASE II TRIAL
    Horton, Janet K.
    Halle, Jan
    Ferraro, Madlyn
    Carey, Lisa
    Moore, Dominic T.
    Ollila, David
    Sartor, Carolyn I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (04): : 998 - 1004
12345